Oncogenic Signaling Pathways in The Cancer Genome Atlas.

Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, Dimitriadoy S, Liu DL, Kantheti HS, Saghafinia S, Chakravarty D, Daian F, Gao Q, Bailey MH, Liang WW, Foltz SM, Shmulevich I, Ding L, Heins Z, Ochoa A, Gross B, Gao J, Zhang H, Kundra R, Kandoth C, Bahceci I, Dervishi L, Dogrusoz U, Zhou W, Shen H, Laird PW, Way GP, Greene CS, Liang H, Xiao Y, Wang C, Iavarone A, Berger AH, Bivona TG, Lazar AJ, Hammer GD, Giordano T, Kwong LN, Mcarthur G, Huang C, Tward AD, Frederick MJ, Mccormick F, Meyerson M, Van Allen EM, Cherniack AD, Ciriello G, Sander C, Schultz N (2018)

Publication Type: Journal article

Publication year: 2018

Journal

Book Volume: 173

Pages Range: 321-337.e10

Journal Issue: 2

DOI: 10.1016/j.cell.2018.03.035

Abstract

Genetic alterations in signaling pathways that control cell-cycle progression, apoptosis, and cell growth are common hallmarks of cancer, but the extent, mechanisms, and co-occurrence of alterations in these pathways differ between individual tumors and tumor types. Using mutations, copy-number changes, mRNA expression, gene fusions and DNA methylation in 9,125 tumors profiled by The Cancer Genome Atlas (TCGA), we analyzed the mechanisms and patterns of somatic alterations in ten canonical pathways: cell cycle, Hippo, Myc, Notch, Nrf2, PI-3-Kinase/Akt, RTK-RAS, TGFβ signaling, p53 and β-catenin/Wnt. We charted the detailed landscape of pathway alterations in 33 cancer types, stratified into 64 subtypes, and identified patterns of co-occurrence and mutual exclusivity. Eighty-nine percent of tumors had at least one driver alteration in these pathways, and 57% percent of tumors had at least one alteration potentially targetable by currently available drugs. Thirty percent of tumors had multiple targetable alterations, indicating opportunities for combination therapy.

Involved external institutions

Memorial Sloan Kettering Cancer Center United States (USA) (US) Université de Lausanne (UNIL) Switzerland (CH) Dana–Farber Cancer Institute United States (USA) (US) Princeton University United States (USA) (US) University of Texas at Dallas (UTD / UT Dallas) United States (USA) (US) Washington University in St. Louis United States (USA) (US) Institute for Systems Biology United States (USA) (US) Bilkent University / Bilkent Üniversitesi Turkey (TR) Van Andel Institute United States (USA) (US) University of Pennsylvania United States (USA) (US) University of Texas MD Anderson Cancer Center United States (USA) (US) TESARO Inc United States (USA) (US) Mayo Clinic United States (USA) (US) Columbia University United States (USA) (US) Fred Hutchinson Cancer Research Center United States (USA) (US) University of Michigan United States (USA) (US) Peter MacCallum Cancer Centre Australia (AU) Houston Texas Medical Center United States (USA) (US) University of California San Francisco (UCSF) United States (USA) (US)

How to cite

APA:

Sanchez-Vega, F., Mina, M., Armenia, J., Chatila, W.K., Luna, A., La, K.C.,... Schultz, N. (2018). Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell, 173(2), 321-337.e10. https://doi.org/10.1016/j.cell.2018.03.035

MLA:

Sanchez-Vega, Francisco, et al. "Oncogenic Signaling Pathways in The Cancer Genome Atlas." Cell 173.2 (2018): 321-337.e10.

BibTeX: Download